Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients
Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients
复制标题
DOI：
10.1002/ijc.21332
复制
发表时间：
2006-01-15
影响因子：
6.4
通讯作者：
Souchelnytskyi, S
中科院分区：
文献类型：
--
作者：
Lomnytska, M;Dubrovska, A;Souchelnytskyi, S
卵巢癌和乳腺癌患者的血浆样本被用来搜索使用二维凝胶电泳和基质辅助激光解吸/电离飞行时间质谱的癌症标志物。截断形式的细胞溶质丝氨酸羟甲基转移酶（cSHMT），T-box转录因子3（Tbx 3）和utrophin异常表达的样本相比，从癌症患者的非癌病例。通过用cSHMT、Tbx 3和utrophin的特异性抗体对血浆样品进行免疫印迹来验证蛋白质的异常表达。研究了79例乳腺癌和39例卵巢癌患者以及31例非癌性疾病患者。我们观察到从疾病早期患者获得的血浆样品中截短的cSHMT、Tbx 3和utrophin的表达增加。我们的数据表明，cSHMT、Tbx 3和utrophin可用作卵巢癌和乳腺癌多参数监测的组分（本文的补充材料可在International Journal of Cancer网站http：//www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html上找到）。(c)2005 Wiley-Liss，Inc.
Plasma samples of ovarian and breast cancer patients were used to search for markers of cancer using 2-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time of flight mass spectrometry. Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples from cancer patients as compared to samples from noncancerous cases. Aberrant expression of proteins was validated by immunoblotting of plasma samples with specific antibodies to cSHMT, Tbx3 and utrophin. A cohort of 79 breast and 39 ovarian cancer patients and 31 individuals with noncancerous conditions was studied. We observed increased expression of truncated cSHMT, Tbx3 and utrophin in plasma samples obtained from patients at early stages of disease. Our data suggest that cSHMT, Tbx3 and utrophin can be used as components of multiparameter monitoring of ovarian and breast cancer (supplementary material for this article can be found on the International Journal of Cancer website at http:// www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html). (c) 2005 Wiley-Liss, Inc.